Skip to content

Study · Not a test of the peptide alone · 2024

3 results

KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.

Zhang L, Li D, Aierken Y, Zhang J, Liu Z, Lin Z, Jiang L, Li Q, Wu Y, Liu Y

Advanced healthcare materials10 Sept 2024Cited by 2 (Europe PMC)

PMID39252648 (opens in a new tab)DOI10.1002/adhm.202402320 (opens in a new tab)PepBankPUB-39252648
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking KPV.

  1. 01AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome

    In mice, KPV-rapamycin nanoparticles significantly inhibited vascular calcification compared with the other treatment groups.

    In plain wordsIn mice, nanoparticles of KPV and rapamycin reduced artery calcification more than the other treatments tested.

    Peptide
    KPV
    Outcome
    DecreaseVascular calcification
    Study

    mousen: not reported in source

    Comparator
    Other treatment groups
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    In vivo and in vitro, KPV-RAPA NPs significantly inhibit VC in mice compared to the other treatment groups.

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

  2. 02AnimalNot a test of KPV aloneAnimal study (in vivo)Mechanism

    KPV-rapamycin nanoparticles inhibited inflammatory responses in the vascular calcification study.

    In plain wordsIn lab and animal tests, nanoparticles of KPV and rapamycin lowered inflammation.

    Peptide
    KPV
    Outcome
    DecreaseInflammatory responses
    Study

    mousen: not reported in source

    Outcome group
    Inflammation markers · Cardiovascular

    Source sentences

    Summary
    Mechanistically, KPV-RAPA NPs inhibit inflammatory responses and activated autophagy.

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

  3. 03AnimalNot a test of KPV aloneAnimal study (in vivo)Mechanism

    KPV-rapamycin nanoparticles activated autophagy in the vascular calcification study.

    In plain wordsIn lab and animal tests, nanoparticles of KPV and rapamycin switched on the cell-cleaning process called autophagy.

    Peptide
    KPV
    Outcome
    IncreaseAutophagy
    Study

    mousen: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Mechanistically, KPV-RAPA NPs inhibit inflammatory responses and activated autophagy.

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.